OncoMatch

OncoMatch/Clinical Trials/NCT06861088

The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

Is NCT06861088 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Kinisoquin™ for venous thromboembolism.

Phase 3RecruitingQuercis Pharma AGNCT06861088Data as of Jun 2026

Treatment: Kinisoquin™The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Kinisoquin™

Cancer type

Pancreatic Cancer

Disease stage

Required: Stage IV, III

metastatic (including recurrent with distant metastases) or locally advanced

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Max 1 prior line

Must have received: chemotherapy — first line

Receiving first line chemotherapy (within 45 days of first dose of study drug) Note: subjects must be either initiating first systemic cancer therapy regimen following initial diagnosis or initiating first cycle of chemotherapy for disease recurrence.

Lab requirements

Blood counts

Platelet count ≥ 100,000/mcL; PT and PTT ≤ 1.5x institutional ULN

Kidney function

Estimated creatinine clearance (CrCl > 30 mL/min)

Liver function

Total bilirubin ≤ 3x ULN without liver metastases and < 5x ULN in presence of liver metastases; AST and ALT ≤ 3x ULN without liver metastases and < 5x ULN in the presence of liver metastases

Participants must have preserved organ and marrow function as defined by: Platelet count ≥ 100,000/mcL. PT and PTT ≤ 1.5x institutional ULN. Total bilirubin ≤ 3x ULN without liver metastases and < 5x ULN in presence of liver metastases. AST and ALT ≤ 3x ULN without liver metastases and < 5x ULN in the presence of liver metastases. Estimated creatinine clearance (CrCl > 30 mL/min).

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Ventura Clinical Trials · Ventura, California
  • Clavis Medical, LLC · Miami Lakes, Florida
  • Beth Israel Deaconess Medical Center · Boston, Massachusetts

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT06861088 currently recruiting?

Yes, this trial is currently recruiting patients.

Is prior treatment required for enrollment?

Yes. Patients must have previously received chemotherapy.

What disease stage is eligible?

Stage IV or III is required.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify